A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression

• Status: Recruiting
• Trial end date: 2023-09-01

Summary

This Phase 3 study is designed to compare the efficacy and safety of mirvetuximab soravtansine vs. investigator's choice chemotherapy in patients with platinum-resistant high-grade epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer, whose tumors express a high-level of FRα. Patients will be, in the opinion of the Investigator, appropriate for single-agent therapy for their next line of therapy. Folate receptor alpha (FRα) positivity will be defined by the Ventana FOLR1 (FOLR1-2.1) CDx assay.

• Phase: Phase 3

Details

• Lead Sponsor: ImmunoGen, Inc.
• Collaborators: European Network of Gynaecological Oncological Trial Groupbs; Gynecologic Oncology Group
• Treatments: Albumin-Bound Paclitaxel; Doxorubicin; Folic Acid; Immunoconjugates; Liposomal doxorubicin; Maytansine; Paclitaxel; Topotecan; Vitamin B Complex